Suven Life Sciences has informed that it has enclosed Press Release of the company titled First Patient randomized in a Phase 2A, Proof of Concept (PoC) clinical trial of SUVN-G3031 for the treatment of Narcolepsy associated with or without Cataplexy in USA.
The above information is a part of company’s filings submitted to BSE.